ClinicalTrials.gg
CompletedNCT03282929Updated Jun 21, 2019

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

A Phase 1 interventional study of Part 1 and Part 2 Group 1 in Anaphylaxis, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in Germany. Open to participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2017, registered Jul 2017).
Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

A single dose, open label, randomized cross-over study to explore the pharmacokinetics and pharmacodynamics of epinephrine in healthy male and female subjects

Read the detailed description

A single dose, open label, randomized cross-over study to explore the pharmacokinetics and pharmacodynamics of epinephrine in healthy male and female subjects with different skin-to-muscle depth (STMD) of the thigh after injections with four different marketed auto-injectors

02

Conditions studied

  • Anaphylaxis

Browse trials for

03

In context

Anaphylaxis

100 studies on the registry are indexed under Anaphylaxis; 20 are open to participants now.

This study's enrollment of 43 is close to the median of 40 across 50 interventional studies indexed under Anaphylaxis.

Browse Anaphylaxis studies →

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.

First submitted after Bausch & Lomb Incorporated became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects, between 18 and 54 years of age (inclusive).
  2. Subjects who are able and willing to give written .
  3. (BMI) between 28.0 and 40.0 kg/m² (inclusive). Weight on Day -1 may not have changed by more than 3 kg compared to screening.
  4. Compressed STMD of 10 mm and above (Part 1+2).
  5. Non-smoker for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of medication (prescription or non-prescription) within 14 days prior to the planned drug administration, except for occasional use of paracetamol or ibuprofen.
  2. Receipt of any of the following medications within the previous 6 months; beta adrenergic blockers, tricyclic antidepressants, monoamine oxidase inhibitors and catechol-O-methyl transferase inhibitors, methylphenidate, amphetamines, any drugs that may sensitize the heart to arrhythmias, including digitalis and quinidine.
  3. History or current evidence of a disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, gastrointestinal or pulmonary diseases especially asthma bronchiale. Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the endpoint analysis if the disease/condition exacerbated during the study.

    History or presence of silent infections, including positive tests for HIV1, HIV2, or C.

  4. Presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
  5. to epinephrine or any of the (e.g. metabisulphite).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Part 1 Group 1

    A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.

    Device: Part 1

  • Experimental
    Part 2 group 1

    300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

    Device: Part 2 Group 1

  • Experimental
    Part 2 Group 2

    500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

    Drug: Part 2 group 2

  • Experimental
    Part 2 Group 3

    300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)

    Device: Part 2 group 3

  • Experimental
    Part 2 Group 4

    300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)

    Device: Part 2 Group 4

Interventions

  • DevicePart 1

    A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order

    Also known as: Group 1

  • DevicePart 2 Group 1

    300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

    Also known as: Group 1

  • DrugPart 2 group 2

    500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)

    Also known as: Group 2

  • DevicePart 2 group 3

    300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)

    Also known as: Group 3

  • DevicePart 2 Group 4

    300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)

    Also known as: Group 4

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed drug concentration

    Time frame: 14 days

  2. tmax

    Time of the maximum drug concentration (obtained without interpolation). If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.

    Time frame: 14 days

07

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, Wegenerstrasse 13 89231, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03282929
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Mar 23, 2017
Primary completion
Sep 28, 2018
Completion
Oct 15, 2018
Last update
Jun 21, 2019

Study contacts

Beate Klaus, MD
principal investigator · Baush and Lomb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion